We have found that abemaciclib, and to a lesser degree palbociclib, lead to apoptosis in CD34+/CD38− LSCs obtained from patients with ASM or MCL, suggesting, that these drugs may contribute to eradication of neoplastic MCs and, hence, have a disease-modulating effect. The gene discussed is CD38; the disease is aggressive systemic mastocytosis.